
Amgen's long-planned $600 million expansion in Thousand Oaks has cleared a major hurdle. The Thousand Oaks City Council voted 5-0 to approve the biotech giant's proposed four-story science and technology center, a project known as Building 50 that will rise at 701 Pauling Drive in Newbury Park.
A Taller Building Than City Rules Typically Allow
The council approved a building height of 75 feet for the project, well above the city's standard 55-foot limit, according to the Thousand Oaks Acorn. That increase is allowed under the Industrial Flex General Plan designation, which permits buildings to reach 75 feet with approval. Rooftop equipment will add further height, sitting at 28 feet above the structure and pushing Building 50's total height, equipment included, to 103 feet.
The new center will be built on the site of the former Building 14 and will include a basement beneath its 377,000 square feet of floor space. Amgen has said the facility is intended to give scientists, engineers and researchers a place to collaborate on treatments for serious diseases. The company broke ground on the project in 2025 and is planning for LEED Gold certification.
Virtual Groundbreaking Came Before Final Sign-Off
Amgen executives and elected officials marked the project's start with a virtual groundbreaking on Oct. 30, 2025, according to Pacific Coast Business Times. Nine days earlier, the city council had unanimously adopted a resolution authorizing concurrent processing of a campus specific-plan amendment and project entitlements, the outlet reported — but at that point, the amendment and entitlements still had to come back to the council at an unspecified date for final approval. The 5-0 vote reported by the Acorn represents that subsequent sign-off.
A separate city public-hearing notice had referenced the 75-foot height figure and a Protected Tree Permit tied to the removal of four oak trees, placing the project within the Industrial Park (M-1) zone of the Amgen Center Specific Plan area, per the City of Thousand Oaks. That notice excerpt did not spell out the full permit list or a complete project description.
Company Executives Frame It as an Investment in the Future
Amgen's Thousand Oaks campus has served as the company's global headquarters since it was founded nearly 40 years before this project's approval. The company says it employs 5,500 Ventura County residents, according to its own website. Amgen executive Ben Chu said Building 50 represents a significant investment in both Amgen's future and the city's future, adding that the project invests in patients, innovation and the community.
Bob Engler called the project a major partnership and a state-of-the-art LEED Gold building, noting that the city had previously sought to create a life-science-focused area and that Amgen is contributing to research while treating the valley environmentally as its own. City official Al Adams described Amgen as an anchor of Thousand Oaks' biotechnology ambitions, saying the expansion complements the city's downtown redevelopment project and that the two efforts will work together to attract young talent and keep young people in the city. Adams also framed the project as part of broader efforts to strengthen the local economy and attract talent.
Part of a Wider Biotech Build-Out
Amgen's Thousand Oaks expansion comes as the company has also announced investments in North Carolina, Ohio and Puerto Rico, broadening its footprint beyond California. The Conejo Valley itself hosts roughly 20 other life science companies, primarily in Thousand Oaks, including Atara Biotherapeutics, Capsida Biotherapeutics, Latigo Biotherapeutics and Tokyo-based Takeda Pharmaceuticals, per Pacific Coast Business Times. Earlier that month, Gilead Sciences broke ground on a development and manufacturing center in Foster City as part of a broader $847 million campus investment, according to the Governor of California's office.
KCLU reported that Amgen's goal is to have its new Thousand Oaks complex operational by 2029, though that date was described as a goal rather than a confirmed completion timeline. With the council's approval now in hand, Building 50 is planned for the site of former Building 14 on Amgen's decades-old campus.









